

NOV 16 2005



Vertex Pharmaceuticals Incorporated
130 Waverly Street • Cambridge, MA 02139-4242
Tel. 617.444.6100 • Fax 617.444.6483
http://www.vrtx.com

FAX TRANSMISSION

| | |
|---------------------|--------------------------------|
| To | USPTO Commissioner for Patents |
| Examiner | Kahsay Habte |
| Fax Number | (571) 273-8300 |
| From | Karen E. Brown |
| Date | November 16, 2005 |
| Application No. | 10/700,936 |
| Attorney Docket No. | VPI/02-123US |
| Total Pages | 60 |

Message or Comment

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence and any documents attached hereto, are being transmitted via facsimile to the United States Patent and Trademark Office, Facsimile Number (571) 273-8300 on November 16, 2005.

Lisa M. Romano

If any problems occur with this fax transmittal, please call (617) 444-6164 immediately.

FAX Number (617) 444-6483 Legal Department

CONFIDENTIALITY NOTICE

The information and the documents transmitted by this teletype are privileged and contain confidential information intended only for the person (s) named above. Any other distribution, copying or disclosure is strictly prohibited. If you have received this teletype in error, please notify us immediately by telephone and return the original to us without making a copy.

RECEIVED
CENTRAL FAX CENTER

NOV 16 2005

Docket No.: VPI/02-123 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/700,936

Confirmation No.: 5983

Filing Date: November 4, 2003

Examiner: Kahsay Habte

Group Art Unit: 1624

Applicants: Randy S. Bethel et al.

For: COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER
PROTEIN KINASESNovember 16, 2005
Cambridge, MassachusettsMail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450TRANSMITTAL LETTER FOR SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT

(a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.

Copy(ies) of references Citation No(s). C1-C4 is attached

Copy(ies) of references Citation No(s). _____ was/were filed in application U.S. Application No(s). _____ filed _____, from which this application claims priority under 35 U.S.C. § 120.).

A copy of the International Search Report received in the corresponding PCT Application No. _____ is attached herewith.

(b) No fee is believed due because:

The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.

The Information Disclosure Statement is being concurrently filed with the above-identified application.

The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).

APPLICANTS: Bethel et al.
U.S.S.N.: 10/700,936

The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

(c) The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and

Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or

The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

(d) The Information Disclosure Statement is being filed on or before the payment of the issue fee; and

Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or

No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and

The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

APPLICANTS: Bethel et al.
U.S.S.N.: 10/700,936

The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Respectfully submitted,

Karen E. Brown
Karen E. Brown, Reg. No. 43,866
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6168
Fax: (617) 444-6483

RECEIVED
CENTRAL FAX CENTER

NOV 16 2005

Docket No.: VPI/02-123 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/700,936

Confirmation No.: 5983

Filing Date: November 4, 2003

Examiner: Kahsay Habte

Group Art Unit: 1624

Applicants: Randy S. Bethel et al.

For: COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER
PROTEIN KINASESNovember 16, 2005
Cambridge, MassachusettsMail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450TRANSMITTAL LETTER FOR SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT

(a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.

Copy(ies) of references Citation No(s). C1-C4 is attached

Copy(ies) of references Citation No(s). _____ was/were filed in application U.S. Application No(s). _____ filed _____, from which this application claims priority under 35 U.S.C. § 120.).

A copy of the International Search Report received in the corresponding PCT Application No. _____ is attached herewith.

(b) No fee is believed due because:

The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.

The Information Disclosure Statement is being concurrently filed with the above-identified application.

The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).

APPLICANTS: Bethel et al.
U.S.S.N.: 10/700,936

The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

(c) The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and

Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or

The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

(d) The Information Disclosure Statement is being filed on or before the payment of the issue fee; and

Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or

No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and

The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

APPLICANTS: Bethel et al.
U.S.S.N.: 10/700,936

The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Respectfully submitted,

Karen E. Brown
Karen E. Brown, Reg. No. 43,866
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6168
Fax: (617) 444-6483

BEST AVAILABLE COPY

NOV 16 2005

Page 1 of 1

| | | | |
|-----------------------------------|--|------------------------|------------------|
| Modified Form 1449/PTO | | Application Number | 10/700,936 |
| | | Filing Date | November 4, 2003 |
| | | First Named Inventor | Randy S. Bethel |
| | | Group Art Unit | 1624 |
| | | Examiner Name | Kahsay Habte |
| | | Attorney Docket Number | VPI/02-123 US |
| (use as many sheets as necessary) | | | |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----------|--------------------------|------------|-------------------------------------|-------|-----------|----------------------------|
| Exam Initials | Cite No. | U.S. Patent Document No. | Issue Date | Name of Patentee(s) or Applicant(s) | Class | Sub Class | Filing Date If Appropriate |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|----------|---------------------------------------|-------------------------------------|---------------------|--------------------|
| Exam Initials | Cite No. | Foreign Patent Document Office Number | Name of Patentee(s) or Applicant(s) | Date of Publication | Translation Yes No |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| OTHER NON PATENT LITERATURE DOCUMENTS | | |
|---------------------------------------|----------|---|
| Exam Initials | Cite No. | Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc. |
| | C1 | LS Steelman et al., "JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL In Cell Cycle Progression And Leukemogenesis", Leukemia 18: 189-218 (2004) |
| | C2 | Francois-Xavier Mahon, "JAK The Trigger", Oncogene 24: 7125-7126 (2005) |
| | C3 | Stefan Faderl et al., "WP-1034, A Novel JAK-STAT Inhibitor, with Proapoptotic and Antileukemic Activity in Acute Myeloid Leukemia (AML)", Anticancer Research 25: 1841-1850 (2005) |
| | C4 | Elisa A. Sudbeck et al., "Structure-based Design of Specific Inhibitors Of Janus Kinase 3 As Apoptosis-Inducing Antileukemic Agents", Clinical Cancer Research, 5: 1569-1582 (1999) |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.